ClinicalTrials.Veeva

Menu

Metastatic or Refractory Soft Tissue Sarcomas and Metronomic Cyclophosphamide: Further Assessment of Efficacy and Safety (MeRCY)

C

Centre Hospitalier Universitaire de Besancon

Status

Completed

Conditions

Sarcoma
Soft Tissue Sarcoma

Study type

Observational

Funder types

Other

Identifiers

NCT06216990
2022/704

Details and patient eligibility

About

Metronomic Cyclophosphamide's use in monotherapy as a palliative treatment against non-resectable and metastatic Soft Tissue Sarcomas relies on small retrospective cohorts' data.

Current litterature needs external validation of its efficacy and safety profile in these settings of usually frail patients.

The investigators assessed further data and aimed to identify predictive factors of metronomic cyclophosphamide impact in metastatic Soft Tissue Sarcomas.

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients over 18
  • with inoperable or metastatic Soft Tissue Sarcoma
  • treated with Metronomic Cyclophosphamide
  • in 3 cancer care institutions located in 2 French regions (Bourgogne and Franche-Comté)
  • between January 2005 and December 2021

Exclusion criteria

  • patients with bone, chondral sarcomas, desmoid, or gastrointestinal stromal tumors

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems